Trading Halt
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Firebrick Pharma Limited has requested a trading halt for its securities pending an announcement regarding a placement. The halt will remain in effect until the market opens on a specified date or until the announcement is made, whichever comes first. The company has stated that it is not aware of any reason why this trading halt request should not be granted.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/trading-halt-1250
Firebrick Pharma Limited on 6ix
Earlier from Firebrick Pharma
- Registration Agreement and Approval of Nasodine in Indonesia
- Appendix 4D & Half-Year Financial Report to 31 December 2025
- December 2025 Quarterly Activity Report & Appendix 4C
- Nasodine Throat Spray Product Launch in Singapore
- Firebrick announces new product Nasodine Throat Spray
Later from Firebrick Pharma
- Firebrick Secures $1.5 million via Placement
- March 2026 Quarterly Activity Report & Appendix 4C
- Investor Update
- Appendix 4E and Annual Report 30 June 2026
- Firebrick receives $293,000 R&D Tax Incentive
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma